My Treatment Approach Enhancing Treatment for Relapsed/Refractory Multiple Myeloma (RRMM): Converting Evidence to Effective Clinical Care

Panelists discuss the treatment of relapsed and refractory multiple myeloma, as well as sequencing strategies aimed at optimizing patient care and minimizing treatment-related side effects,presenting two real-world patient cases and explain our treatment approach, highlighting how they incorporate recent data into our practice.

EP. 1: Exploring the Treatment Options for RRMM

May 9th 2025

Panelists discuss how treatment selection for relapsed/refractory multiple myeloma hinges on the pace of disease progression, with options ranging from second autologous transplants to chimeric antigen receptor T-cell therapies and bispecific antibodies, each tailored to patient status, prior therapy, and urgency of intervention.

EP. 2: Sequencing the Available T Cell– Engaging Therapies, and the Role of Bridging/Holding Therapy in RRMM

May 9th 2025

Panelists discuss how effective sequencing and bridging strategies for T-cell engaging therapies in (relapsed/refractory multiple myeloma (RRMM) rely on using chimeric antigen receptor T-cell therapy (CAR T) first when feasible, while carefully selecting bridging treatments—such as nonoverlapping bispecifics or selinexor regimens—to manage disease without compromising CAR T readiness or long-term immune function.

EP. 3: Exploring T-Cell Fitness Strategies to Optimize Clinical Outcomes in RRMM

May 16th 2025

Panelists discuss how bridging strategies such as selinexor, immunomodulatory drugs (IMiDs), and, potentially, immune checkpoint inhibitors (ICIs) can preserve or enhance T-cell fitness prior to chimeric antigen receptor T-cell therapy (CAR T), offering a dual benefit of disease control and improved therapeutic response in relapsed/refractory multiple myeloma (RRMM) patients.

EP. 4: Discussing the Treatment Options for RRMM Following Progression After BCMA CAR T Therapy

May 16th 2025

Panelists discuss how various treatment options, including selinexor-based regimens, B-cell maturation antigen (BCMA)–targeted therapies, bispecific antibodies, and CELMoDs, can be used to manage relapsed/refractory multiple myeloma following progression on BCMA-directed chimeric antigen receptor T-cell therapy (CAR T).

EP. 5: Important Patient and Clinical Considerations When Choosing Therapy in RRMM Following CAR T Therapy

May 23rd 2025

Panelists discuss how selinexor offers convenient oral administration, bispecific antibodies provide high response rates but may present toxicity risks, and cytotoxic chemotherapy is effective for aggressive disease but carries significant adverse effects and risks.

EP. 6: Highlighting Selinexor in the RRMM Setting After CAR T Therapy

May 23rd 2025

Panelists discuss how recurrent infections may influence the choice of selinexor over bispecific antibodies, with selinexor offering a safer option for patients with high infection risk, and dosing considerations such as once-weekly administration and potential dose reductions still providing clinical benefit.

EP. 7: Bispecific Antibodies for the Treatment of RRMM in the Post CAR T Setting

May 30th 2025

Panelists discuss how the transition from chimeric antigen receptor T-cell therapy (CAR T) to bispecific antibodies depends on disease progression and clinical status, with the choice of bispecific antibody being guided by prior therapy and target antigen, preferring B-cell maturation antigen (BCMA) bispecifics for BCMA-exposed patients and GPRC5D bispecifics for those with BCMA-relapsed disease.

EP. 8: Practical Recommendations for Community Oncologists Treating RRMM

May 30th 2025

anelists discuss how the rapidly evolving treatment landscape for relapsed/refractory multiple myeloma requires personalized strategies, emphasizing the importance of patient-centric decision-making, effective therapy sequencing, and ongoing research to improve both efficacy and quality of life

x